Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer : Correlation with PSA and Clinical Stage by Wu, Xingchen et al.
Research Article
DynamicContrast-EnhancedImagingasaPrognosticTool inEarly
Diagnosis of Prostate Cancer: Correlation with PSA and
Clinical Stage
Xingchen Wu ,1,2,3 Petri Reinikainen,1,2 Mika Kapanen,1,4 Tuula Vierikko,3
Pertti Ryymin,3,4 and Pirkko-Liisa Kellokumpu-Lehtinen1,2
1Department of Oncology, Tampere University Hospital, Tampere, Finland
2Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
3Department of Radiology, Medical Imaging Centre, Tampere University Hospital, Tampere, Finland
4Department of Medical Physics, Medical Imaging Centre, Tampere University Hospital, Tampere, Finland
Correspondence should be addressed to Xingchen Wu; xingchen.wu@uta.
Received 10 April 2018; Accepted 22 July 2018; Published 19 September 2018
Academic Editor: Orazio Schillaci
Copyright © 2018 XingchenWu et al.­is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and Purpose. Although several methods have been developed to predict the outcome of patients with prostate cancer,
early diagnosis of individual patient remains challenging. ­e aim of the present study was to correlate tumor perfusion parameters
derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and clinical prognostic factors and further to
explore the diagnostic value of DCE-MRI parameters in early stage prostate cancer. Patients andMethods. Sixty-two newly diagnosed
patients with histologically proven prostate adenocarcinoma were enrolled in our prospective study. Transrectal ultrasound-guided
biopsy (12 cores, 6 on each lobe) was performed in each patient. Pathology was reviewed and graded according to the Gleason system.
DCE-MRI was performed and analyzed using a two-compartmental model; quantitative parameters including volume transfer
constant (Ktrans), reux constant (Kep), and initial area under curve (iAUC) were calculated from the tumors and correlated with
prostate-specic antigen (PSA), Gleason score, and clinical stage. Results. Ktrans (0.11± 0.02min−1 versus 0.16± 0.06min−1; p< 0.05),
Kep (0.38± 0.08min− 1 versus 0.60± 0.23min− 1; p< 0.01), and iAUC (14.33± 2.66mmoL/L/min versus 17.40± 5.97mmoL/L/min;
p< 0.05) were all lower in the clinical stage T1c tumors (tumor number, n  11) than that of tumors in clinical stage T2 (n  58).
Serum PSA correlated with both tumor Ktrans (r  0.304, p< 0.05) and iAUC (r  0.258, p< 0.05). Conclusions. Our study has
conrmed that DCE-MRI is a promising biomarker that reects the microcirculation of prostate cancer. DCE-MRI in combination
with clinical prognostic factors may provide an eective new tool for the basis of early diagnosis and treatment decisions.
1. Introduction
Prostate cancer is the second leading cause of cancer-related
death and the most frequently diagnosed male malignant
disease in the Nordic countries [1]. Early detection of
prostate cancer permits appropriate and timely management
of the disease, and prognostic biomarkers can help clinicians
to make a proper decision for treatment of individual pa-
tients and to avoid unnecessary treatments [2]. Although
several methods have been developed to predict outcome
of patients with prostate cancer, prognosis evaluation of
individual patient remains challenging. Recent studies
demonstrate that multiparametric magnetic resonance im-
aging (MP-MRI), consisting of T1-weighted, T2-weighted,
diusion-weighted imaging (DWI), and dynamic contrast-
enhanced MRI (DCE-MRI), has emerged as a useful tool
not only for localizing prostate cancer foci, but also for
assessing tumor aggressiveness [3]. DWI allows to quantify
the randommotion of water molecules in tissue by means of
apparent diusion coe£cient (ADC) measurements and
provides information on tissue cellularity, tortuosity of
extracellular space, and cell membrane integrity, thereby
dierentiating noncancerous and cancer lesions [4]. DCE-
MRI is a relatively novel imaging modality that allows to
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measure properties of tissue microvasculature resulting
from tumor angiogenesis and improving tumor detection
and response assessment [5]. *e most commonly used
DCE-MRI parameter that reﬂects vascular permeability is
the volume transfer constant (Ktrans) [6]. Ktrans represents
the rate at which the contrast agent transfers from the blood
to the interstitial space, which indicates the tumor micro-
circulation and the surface inﬁltration area. In contrast, the
reﬂux constant (Kep) reﬂects the rate at which the contrast
agent transfers from the extravascular extracellular space
back to the blood. *e extravascular extracellular leakage
volume fraction (Ve�Ktrans/Kep) predominantly reﬂects the
percentage of contrast agent in the extravascular extracel-
lular space [6]. In addition, the semiquantitative parameter
initial area under curve (iAUC) is associated with tumor
blood inﬂux, perfusion, and interstitial space and represents
the general tumor blood ﬂow, overall perfusion, and tumor
interstitial space index [6].
*e aim of the present study was to correlate tumor
perfusion parameters derived from DCE-MRI and clinical
prognostic factors and further to explore if we can separate
very early tumors from relatively advanced ones with DCE-
MRI-derived parameters for decision making in early stage
prostate cancer.
2. Materials and Methods
2.1. Patients. Seventy-one consecutive patients with histo-
logically proven prostate adenocarcinoma were enrolled in
our prospective clinical trials to develop hypofractionated
image-guided and intensity-modulated radical radio-
therapy. *e study identiﬁer at www.ClinicalTrials.gov is
NCT02319239. *e inclusion and exclusion criteria have
been described in details in our previous publication [7].
Brieﬂy, newly diagnosed adult patients with one or two of
the intermediate-risk features (Gleason score 7, staging
T2b-T2c, PSA 10–20 ng/mL) according to the National
Comprehensive Cancer Network (NCCN) criteria [8], and
patients were suitable for MRI examination. No patients
received neoadjuvant or adjuvant hormonal treatment.*e
study was approved by the Ethics Committee of Tampere
University Hospital (Nr. R14009), and all patients gave
written informed consent prior to study entry. Patients
underwent physical examination, digital rectal examina-
tion, and standard laboratory tests including serum
prostate-speciﬁc antigen (PSA).
2.2. Histological Analysis. Transrectal ultrasound-guided
biopsy (12 cores, 6 on each lobe) was performed in each
patient. Six biopsy cores were embedded in one paraﬃn
block. Pathology was reviewed and graded according to the
Gleason system. Major criteria include an inﬁltrative glan-
dular growth pattern and an absence of basal cells and
nuclear atypia in the form of nucleomegaly and nucleolo-
megaly. *e diagnosis was based on the microscopic ap-
pearance of slides stained using haematoxylin and eosin. In
diﬃcult cases, basal cell absence has been conﬁrmed by
immunohistochemical stains for basal cell markers.
2.3. Multiparametric MRI Acquisition. Multiparametric MR
imaging was acquired using a 3 Tesla MR System (Siemens
Trio-Tim, Erlangen, Germany) with a combination of 6-
channel body matrix coil and 6 elements of 24-channel spine
matrix coil positioned around the pelvis to cover the prostate.
Tri-planar T2-weighted turbo spin echo images from below
the prostatic apex to above the seminal vesicles were obtained.
DWI was acquired with a single-shot echoplanar sequence on
the axial plane using three b values (50, 400, and 800 s/mm2)
and with the same orientation and location used to acquire
axial T2-weighted images. DCE-MRI was performed with
axial T1-weighted 3D volumetric interpolated breath-hold
examination (VIBE) sequence that covers the entire pros-
tate in consecutive sections. To determine the T1 relaxation
time in the tissue before the arrival of contrast agent, the
DCE-MRI included two precontrast 3D VIBE imaging se-
quences that had diﬀerent ﬂip angles (2° and 13°). *ese
sequences were followed by a DCE series on the axial plane
after gadolinium (Gd)-DOTA (0.2ml/kg Dotarem®) in-jection, with a temporal resolution of 8 seconds and an ac-
quisition time of 4minutes 40 seconds.*e contrast agent was
administered using a power injector (Medrad Spectris Solaris
EP, Bayer Medical Care Inc, PA, USA) followed by a 20ml
saline ﬂush injection at a ﬂow rate of 2.5ml/s. To minimize
postbiopsy artifact, MRI was performed 6–10 weeks after the
prostate cancer conﬁrmation by biopsy. For imaging pa-
rameters, see Table 1.
2.4. MR Image Analysis. All MR images were reviewed and
analyzed on a syngo Multimodality Workplace (Siemens
Healthcare). Voxelwise MRI signal enhancement time
curves were ﬁtted according to a pharmacokinetic model
using Tissue 4D software (Siemens Healthcare). First,
a motion correction has been performed, which registered
all volumes of the time series to a user-selected reference
volume to reduce the eﬀect of patient and physiological
motion during the DCE image acquisition. After the reg-
istration of the morphological image and the precontrast
image, an oval-shaped or irregular-shaped region of interest
(ROI) was drawn on the prostate cancer foci. ROIs were
drawn in early enhancing region of DCE-MRI and with the
DWI b800, ADCmap, and T2-weighted image as references.
T1 map calculation of precontrast was a prerequisite for
pharmacokinetic modeling. T1 ﬁtting was restricted to pixels
with values above a noise level value (>20), and the re-
spective values were automatically calculated by the system
as a function of the entered contrast agents. For the Tofts
modeling [6], Tissue 4D provides arterial input function
(AIF) that are modeled using a biexponential function with
three diﬀerent modes (fast, intermediate, and slow).*e AIF
was chosen according to the fast sampling method to cal-
culate kinetic parameters [9]. Parametric maps were cal-
culated, and Ktrans, Kep, Ve, and iAUC of the selected ROI
were automatically estimated by the software.
*e ADC value of each identiﬁed tumor lesion was
measured directly on the parametric ADC maps. *e
ADC map was reviewed simultaneously with the corre-
sponding high b value DW images, T2-weighted images, and
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precontrast T1-weighted images. *e slice of the ADC map
containing the largest tumor extent was selected for analysis,
and a ROI was drawn in the center of the tumor excluding
the tumor edges. *e mean ADC value and the size of the
selected tumor area were generated at the workstation and
recorded for analysis.
A prostate cancer was deﬁned on each MRI as follows:
a hypointense region relative to the adjacent parenchyma on
T2-weighted image; a region with a low ADC value relative
to the adjacent parenchyma on the ADC map; and a region
with early wash-in and wash-out of contrast medium relative
to the adjacent parenchyma on DCE-MRI. Precontrast T1-
weighted images were used to identify postbiopsy hemor-
rhage (as an area with high signal intensity) to rule out false-
positive ﬁndings.
2.5. Statistical Analysis. Statistical analysis was performed
with SPSS (version 23.0, SPSS Inc., Chicago, Illinois, USA).
A two-sided nonparametric Mann–Whitney U test was used
to compare the patients age, PSA, tumor size, ADC, Ktrans,
Kep, Ve, or iAUC between the peripheral and transitional
zone tumor groups, between Gleason score 3 + 3 and 3 + 4
groups, and between diﬀerent clinical stages. Spearman’s
correlation coeﬃcient was used to evaluate the correlation
between tumor size, ADC, Ktrans, Kep, Ve, iAUC, Gleason
score, and serum PSA; p values less than 0.05 were con-
sidered signiﬁcant.
3. Results
3.1. Patient Characteristics. No suspicious lesion was found
on MRI in 7 out of the 71 patients with a biopsy proven
prostate cancer; two patients had no DCE images due to
allergy to the contrast agent. Sixty-nine lesions were detected
in the prostate of the remaining 62 patients (age: mean± SD:
70± 5 years, range from 60 to 79 years). Ten patients had
clinical stage T1c and 52 had T2 (16 in T2a, 8 in T2b, and 28
in T2c) tumors according to TNM classiﬁcation for prostate
cancer. *e serum PSA value (mean± SD) was 9.5±
3.7 ng/mL, with the range from 3.4 to 19.1 ng/mL.
3.2. Pathological Results. *ere were 19 patients with
a Gleason score 3 + 3, 41 with a Gleason score 3 + 4, and 2
with a Gleason score 4 + 3 tumor.
None of the measured parameters, including patients’ age,
serum PSA, and DWI- and DCE-MRI-derived parameters,
were diﬀerent between Gleason score 3 + 3 and 3+ 4 tumor
groups.
3.3. Tumor Location. *emajority of the tumors were in the
peripheral zone (52, 75%), and the other 17 tumors were in
the transitional zone.
*ere was no signiﬁcant diﬀerence of the patients’ age,
serum PSA, tumor ADC, Ktrans, or iAUC between the pe-
ripheral and transitional zone tumor groups (Table 2).
(a) *e size of peripheral zone tumors (lesion number,
n � 52) was smaller than that of the transitional zone
tumors (n � 17) (0.68± 0.41 cm2 versus 0.93±
0.59 cm2; p< 0.05).
(b) Kep was higher in the peripheral zone tumors (lesion
number, n � 52) than that of the transitional zone
tumors (n � 17) (0.59± 0.21min−1 versus 0.49±
0.24min−1; p< 0.05).
(c) Ve was lower in the peripheral zone tumors (lesion
number, n � 52) than that of the transitional zone
tumors (n � 17) (0.27± 0.08 versus 0.32± 0.07;
p< 0.05).
3.4. DCE-MRI-Derived Parameters. Prostate cancer showed
earlier and more pronounced enhancement than sur-
rounding normal prostate tissue (example Figure 1). Fifty-
nine patients had perfusionMRI ﬁndings of at least one focal
enhancing tumor in the prostate. In three patients, focal
lesions were not obvious on the DCE images; all these 3
patients had clinical stage T2c tumors.
Ktrans (0.11± 0.02min−1 versus 0.16± 0.06min−1;
p< 0.05), Kep (0.38± 0.08min−1 versus 0.60± 0.23min−1;
p< 0.01), and iAUC (14.33± 2.66mmoL/L/min versus
17.40± 5.97mmoL/L/min; p< 0.05) were all lower in the
clinical stage T1c tumors (n � 11) than that of the clinical
stage T2 tumors (n � 58) (Figures 2(a)–2(c)).
3.5. Serum PSA Value. *ere were no signiﬁcant diﬀerences
of the serum PSA levels between clinical stage T1c (n � 10)
and T2 patients (n � 52) (8.2± 4.5 ng/mL versus 9.8±
3.6 ng/mL; p � 0.151) (Figure 2(d)).
Table 1: Sequence parameters for 3T multiparametric MRI with the body and spine matrix combination coil system.
Sequence Pulse sequence TR (msec) TE (msec) FA (°) FOV (mm) ACQmatrix Slice/gap (mm)
Axial DWI, b� 50, 400,
and 800 s/mm2 SE-EPI 3800 77 90 221× 260 102×160 3.6/0
Axial T2W TSE 4000 100 90 200× 200 288× 320 3/0.6
Sagittal T2W TSE 5000 100 90 200× 200 288× 320 3/0.6
Coronal T2W TSE 5000 100 90 200× 200 288× 320 3/0.6
Axial 3D∗ FLASH GRE 4.9 1.7 2 and 13 260× 260 138×192 3/0
Axial 3D DCE FLASH GRE 4.9 1.7 12 260× 260 138×192 3.6/0
SE, spin echo; EPI, echo planar imaging; TSE, turbo spin echo; FLASH, fast low angle shot; GRE, gradient recalled echo; TR, repetition time; TE, echo time;
FA, ﬂip angle; ACQ matrix, acquisition matrix. ∗Sequence for the measurement of T1 relaxation time.
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3.6. 3e Correlations between PSA and MRI Parameters.
Serum PSA correlated with both tumor Ktrans (r � 0.317,
p � 0.012) (Figure 3(a)) and tumor iAUC (r � 0.258,
p � 0.043) (Figure 3(b)).
No correlation was found between serum PSA and tu-
mor ADC value.
4. Discussion
A reliable diagnostic test should be able to provide an early
prostate cancer diagnosis and minimize the amount of
unnecessary biopsies or treatments. From this perspective,
morphological MRI is a good candidate for prostate can-
cer investigation as it provides high-contrast and high-
resolution images of the prostate. However, no single
MRI sequence is suﬃcient to characterize prostate cancer.
Each of the functional MR components has clinical ad-
vantages and limitations. Early promising data suggest that
MP-MRI, which is performed concurrently with anatomical
and functional techniques, is the most sensitive and speciﬁc
imaging tool for lesion detection, characterization, and
staging of prostate cancer [3]. Our study revealed a corre-
lation between tumor Ktrans and serum PSA in patients with
early stage prostate cancer. *is ﬁnding is consistent with
previous publications [10, 11]. In addition, we detected
a correlation between tumor iAUC and serum PSA. *ese
may be explained by the altered vascular permeability of
tumor microvessels and lymphatic system [12]. Neo-
vascularity has been demonstrated to be a prerequisite for
tumor growth and metastasis [13]. Abnormal angiogenesis
in the tumor tissue lead to higher microvessel density, which
is represented by leakage, twisted morphology, vascular
wall expansion, and crosslinking [14]. Many scientists have
suggested microvessel density as a prognostic and a pre-
dictive factor [15]. However, microvessel density measure-
ment depends on the availability of postoperative tissue or
biopsy materials, and it is a static assessment rather than
information on vascular function. *erefore, there were
Table 2: Comparison of the 62 patients with peripheral and transitional zone prostate cancer (46 versus 16): age, tumor size, and DWI- and
DCE-derived tumor parameters.
Total n � 69 mean± SD Peripheral n � 52 mean± SD Transitional n � 17 mean± SD p value
Age (years) 70± 5 70± 5 70± 4 0.974
PSA (ng/mL) 9.5± 3.7 9.7± 3.9 9.1± 3.3 0.552
Area of tumor (cm2) 0.74± 0.47 0.68± 0.41 0.93± 0.59 0.037
ADC (×10−3mm2/s) 0.87± 0.16 0.89± 0.17 0.82± 0.13 0.259
Ktrans (min−1) 0.15± 0.05 0.15± 0.05 0.14± 0.06 0.743
Kep (min−1) 0.57± 0.22 0.59± 0.21 0.49± 0.24 0.048
Ve 0.28± 0.08 0.27± 0.08 0.32± 0.07 0.026
iAUC (mmoL/L/min) 16.70± 5.69 17.26± 5.51 15.86± 6.21 0.626
PSA, prostate-speciﬁc antigen; ADC, apparent diﬀusion coeﬃcient; Ktrans, volume transfer constant; Kep, reﬂux constant; Ve, extravascular extracellular
leakage volume fraction; iAUC, initial area under curve; n, number of tumors.
(a) (b) (c) (g)
(d) (e) (f)
Figure 1: Transverse prostate MR images from a 69-year-old male patient with biopsy proven prostate cancer (Gleason score 3 + 4 and
serum PSA 6.6 ng/mL): (a) T2-weighted image showing in the transitional zone a hypointense area without clear border; (b) ADC map:
transitional zone hypointense region with a clear border, with ADC value of 0.75×10−3mm2/s; (c) T1-weighted image early enhancement
map: the enhanced region of interest 1 (ROI1, red line) corresponds to the tumor, and ROI 2 (green line) was selected from normal prostate
tissue as healthy control; (d) Ktrans map: ROI 1 Ktrans 0.120 min−1 and ROI 2 Ktrans 0.048 min−1; (e) Kep map: ROI 1 Kep 0.657 min−1 and ROI
2 Kep 0.327 min−1; (f ) iAUCmap: ROI 1 iAUC 14.976 mmoL/L/min and ROI 2 iAUC 6.871 mmoL/L/min; (g) enhancement kinetics pattern
from the two ROIs: the time-intensity curves were obtained from dynamic contrast-enhanced MRI. ROI1 showing a higher peak en-
hancement and an early wash-in and wash-out of contrast medium compared with ROI 2.
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controversial results between microvessel density and
prostate cancer progression and grade [16]. In contrast, the
distribution of Gd-DOTA in DCE-MRI is determined not
only by microvessel density but also by vessel permeability
and size of the extravascular extracellular space. DCE-MRI
not only provides more details in tumor morphology but
also allows to assess contrast agent kinetics and thus allows
to improve detection and grading of prostate cancer.
DCE-MRI can be used to assess noninvasively the
functional aspects of microcirculation of tissues. DCE-MRI
relies on the fact that a bolus of contrast agent passing
through the capillary bed is transiently conned within the
vascular space before passing rapidly into the extravascular
extracellular space at a rate determined by the permeability
of the microvessels, their surface area, and blood ow
[17, 18]. In DCE-MRI, the distribution of the contrast agent
is repeatedly measured, allowing the evaluation of the
tumor microcirculation in vivo and enabling the malignancy
or benignancy of the tumor to be quantitatively distin-
guished [19]. Neoangiogenesis plays a vital role in the
growth, progression, and metastasis process of prostate
cancer [20, 21]. Microvessel density in prostatic carcinoma
has also been shown to be an independent predictor of the
pathological stage [13]. In consistent, we found that the
tumor Ktrans, Kep, and iAUC were all lower in smaller tumors
(T1c) than in larger local tumors (T2) in biopsy proven
prostate cancer. To our knowledge, this is the rst report that
revealed DCE-MRI-derived parameters can separate very
early stage tumors and relatively advanced tumors in clin-
ically localized prostate cancer. Quantication of tumor
angiogenesis by DCE-MRI may allow stratication of pa-
tients to type of treatment.
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Figure 2: Comparison of tumorKtrans, Kep, iAUC, and serumPSA level in patients with dierent clinical stages of prostate cancer. (a)Ktrans (0.11±
0.02min−1 versus 0.16± 0.06min−1; p< 0.05), (b) Kep (0.38±0.08min−1 versus 0.60± 0.23min−1; p< 0.01), and (c) iAUC (14.33±
2.66mmoL/L/min versus 17.40±5.97mmoL/L/min; p< 0.05) were all lower in clinical stage T1c tumors than that in clinical stage T2 tumors;
(d) there was no signicant dierence of serumPSA between clinical stage T1c and T2 patients (8.2±4.5 ng/mL versus 9.8±3.6 ng/mL;p  0.151).
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Figure 3: Correlations between serum PSA and DCE-MRI-derived tumor parameters in the 62 patients with prostate cancer. (a) Serum PSA
correlated with tumor Ktrans (r  0.317, p< 0.05); (b) Serum PSA correlated with tumor iAUC (r  0.258, p< 0.05).
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Serum PSA is elevated as a result of disruption of the
prostatic architecture in the presence of prostate disease
and injury, and PSA screening helps to diagnose prostate
cancer earlier, at lower clinical stages and with lower
Gleason score [22]. However, we did not ﬁnd signiﬁcant
diﬀerence of the serum PSA levels between the tumors in
clinical stage T1c and those with relatively extent diseases,
for example, clinical stage T2. Serum PSA is not a speciﬁc
marker for prostate cancer because of variable contribu-
tion to PSA from benign tissue and the nonlinear re-
lationship between grade and PSA, which lead to overlap
in PSA levels between diﬀerent clinical stages as shown
also in previous studies [23]. As a result, serum PSA level
cannot be used alone to accurately predict disease extent
for any individual patient. DCE-MRI play a role in con-
junction with PSA for localizing suspicious lesions for
biopsy, improving speciﬁcity, and identifying those tu-
mors that are more likely to cause death if they are
left untreated.
*e Gleason score reﬂects the tumor aggressiveness and
is an important predictor of outcome in patients with
prostate cancer [2]. Correlation between the Gleason score
and DCE-MRI-derived parameters may have been expected,
because the Gleason scores have been shown to correlate
with microvessel density measurements [13]. However, we
did not detect any signiﬁcant diﬀerence of the DCE-derived
parameters between patients with Gleason score 3 + 3 and 3
+ 4. *e lack of diﬀerences may be explained by the het-
erogeneity of tumor tissues [24] and the histological sam-
pling errors inherent in needle biopsy. Secondly, our patients
were selected with one or two of the intermediate-risk
features. *erefore, the diﬀerences of their disease
extent/magnitude are relatively small compared with pre-
vious publications [10, 11].
Our study has a few limitations: ﬁrstly, the MRI was
performed after biopsy. We were not sure, if the tumor ADC
value and DCE parameters had been measured at the biopsy
sites. Secondly, we were unable to evaluate the correlation
between MRIs and histopathological features accurately
because we did not obtain surgical specimens. *ere have
been concerns about the probability of undergrading
prostate cancer by biopsy due to tumor heterogeneity.
*irdly, all patients underwent needle biopsies before MRI
examinations, implying that hemorrhagic or inﬂammatory
changes caused by this procedure might have aﬀected the
MRIs. However, we excluded visible bleeding with the help
of precontrast T1-weighted images, and the time interval
between biopsy and MRI was long (6–10 weeks) enough for
biopsy wound healing.
5. Conclusions
In conclusion, the present study has conﬁrmed that DCE-
MRI is a promising biomarker that reﬂects the microcir-
culation of prostate cancer. DCE-MRI-derived quantitative
parameters in combination with clinical prognostic factors
may provide an eﬀective pretreatment diagnosis modality
for early prostate cancer, especially for those with negative
biopsy.
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